PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Net Receivables Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x CRVO's -12.64%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x CRVO's -0.28%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
100.00%
Higher Other Assets Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-99.84%
Less than half of CRVO's 27.59%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Less than half of CRVO's 317.33%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
100.00%
Less than half of CRVO's -95.75%. David Dodd sees fewer expansions in other current obligations.
13.77%
Less than half of CRVO's -70.68%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
11.40%
Less than half of CRVO's -70.68%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.71%
Below half CRVO's 9.81%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
110.36%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-11.42%
Below half CRVO's 86.67%. Michael Burry sees potential underperformance in building shareholder capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.32%
Less than half of CRVO's 317.33%. David Dodd sees less overall debt expansion vs. competitor.
10.35%
Less than half of CRVO's 404.43%. David Dodd sees better deleveraging or stronger cash buildup than competitor.